Editor-in-Chief Sue Yom hosts Dr. Karin Lindberg, a Clinical Oncologist at the Karolinska Institute in Sweden and the supervising author of a new paper this month, "Expanded HILUS trial - a pooled analysis of risk factors for toxicity from SBRT of central and ultra-central lung tumors," and Dr. David Palma, a Radiation Oncologist at the London Health Sciences Centre who co-authored the accompanying editorial, "Beyond the HILUS Trial: How Can We Improve the Safety of SABR for Ultra-Central Thoracic Tumors?" Dr. Palma also describes the design and findings of the new clinical trial SUNSET, which he presented in the Multidisciplinary Thoracic Cancer Symposium plenary session simultaneously with this podcast release.